tldrdaily.news logo
Tag

Esketamine

All articles tagged with #esketamine

health1 year ago

"Postpartum Depression Risk Reduced with Immediate Ketamine Treatment, Study Shows"

A trial found that administering a low dose of esketamine, a potent form of ketamine, to new mothers immediately after childbirth reduced the risk of postnatal depression by about three-quarters. The study suggests that this medication, used as an anaesthetic and antidepressant, should be considered for new mothers showing symptoms of depression during pregnancy. Postnatal depression affects one in ten women after giving birth and can involve intense feelings of sadness, anxiety, and exhaustion. Existing treatments for postnatal depression include talking therapy and traditional antidepressants, but esketamine could offer a more effective and faster-acting alternative.

via Daily Mail|
#esketamine#health#ketamine
neuroscience2 years ago

Uncovering Genetic and Therapeutic Breakthroughs in Treatment-Resistant Depression

Researchers have identified a gene called LHPP that interacts with stress and plays a crucial role in treatment-resistant Major Depressive Disorder (MDD) using an animal model. Increased expression of LHPP worsened depression-like behaviors in stressed mice, while esketamine showed promise in alleviating this form of depression. The study highlights the complex interplay between genetic risks and environmental factors in the development of MDD and suggests LHPP as a potential therapeutic target for MDD treatment.

via Neuroscience News|
#animal-model#esketamine#lhpp-gene
health2 years ago

Esketamine Nasal Spray Outperforms Quetiapine for Treatment-Resistant Depression

Esketamine nasal spray has shown promising results in a major clinical trial, outperforming standard treatments for treatment-resistant depression (TRD). In the study, 28% of patients achieved remission in eight weeks with esketamine, compared to 18% with quetiapine. The long-term data also revealed that esketamine was more effective in sustaining remission without relapse. While esketamine has been approved by regulatory agencies, access to evidence-based treatments for TRD remains limited in many countries. Further research is needed to identify predictive markers for treatment responsiveness and explore ways to improve and sustain remission rates. Advocacy and governmental action are crucial to ensure patients have access to effective treatment options.

via SciTechDaily|
#antidepressant#clinical-trial#esketamine
health2 years ago

Head-to-Head Trial Declares Esketamine Superior to Quetiapine for Treatment-Resistant Depression

A head-to-head trial sponsored by Janssen, the maker of esketamine spray, compared the effectiveness of nasal esketamine spray to quetiapine, an extended-release antipsychotic, in patients with treatment-resistant depression. The study found that esketamine was more effective than quetiapine when taken in combination with SSRIs and SNRIs. At eight weeks, 27% of patients treated with esketamine were in remission compared to 17% of those taking quetiapine. Esketamine patients in remission at week eight were more likely to remain in remission until week 32. Patients taking esketamine were also more likely to adhere to the treatment. The study suggests that a longer initial course of esketamine treatment may be more effective and calls for further research to identify patients who are likely to respond positively to the drug.

via STAT|
#antidepressants#clinical-trial#esketamine